ArticlePloS one2026
Appendicular-to-trunk lean mass ratio resolves the height-based normalization paradox in low muscle mass and metabolic syndrome: A population-based cross-sectional study.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Whether height-based normalization indices for appendicular lean mass (ALM) are metabolically neutral remains uncertain, because such indices may be influenced by adiposity. We evaluated ALM normalized to trunk lean mass (ALM/TLM) - both with bone mineral content excluded - as a normalization strategy potentially less susceptible to adiposity-related distortion. Using the Korea National Health and Nutrition Examination Survey 2008-2010, we analyzed 3,176 adults aged ≥65 years (1,373 men; 1,803 women) for body composition by dual-energy X-ray absorptiometry. Sex-specific Class I and Class II cut-offs were derived from a healthy young reference group aged 20-39 years (n = 3,727) at 1 SD and 2 SD below the young-adult mean. Metabolic syndrome (MetS) was defined by NCEP-ATP III criteria with population-specific waist cut-offs. Survey-weighted regression models were adjusted for age, smoking, alcohol, and physical activity. The appendicular skeletal muscle mass index (ASMI; ALM/height2) correlated positively with fat mass index (FMI) (men r=+0.288; women r=+0.358; both p < 0.001), whereas ALM/TLM correlated negatively with FMI (men r=-0.199; women r=-0.243; both p < 0.001). ASMI Class I low muscle mass showed an inverse association with MetS (men odds ratio [OR] 0.496, 95% confidence interval [CI] 0.388-0.636; women OR 0.475, 95% CI 0.328-0.686). In contrast, ALM/TLM Class II showed positive associations with MetS (men OR 2.779, 95% CI 2.074-3.722; women OR 2.701, 95% CI 1.680-4.340; both p < 0.001). The inverse ALM/TLM-HOMA-IR association persisted after FMI adjustment (men β=-0.131, p < 0.001; women β=-0.065, p = 0.007). ASMI correlated positively with adiposity, while ASMI-defined low muscle mass was inversely associated with MetS, suggesting that ASMI may partly reflect body size/adiposity rather than relative muscle depletion alone; this inverse association should not be interpreted as protective. By contrast, ALM/TLM-defined low muscle mass showed consistently positive associations with MetS across adiposity strata, supporting further evaluation of ALM/TLM, although its clinical validity remains unestablished.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.